teroxirone

**Teroxirone** is a synthetic triazene triepoxide small molecule with **antineoplastic (anticancer) activity**. Its mechanism involves **alkylation and cross-linking of DNA**, leading to the inhibition of DNA replication, cytotoxicity, and induction of apoptotic cell death. Preclinical studies showed cytotoxic activity against leukemia cell lines resistant to cyclophosphamide and against human lung cancer cells, partly via mitochondrial injury and p53-mediated apoptosis. Teroxirone was initially developed by Henkel and entered clinical trials for cancer, but development was discontinued due to significant dose-limiting toxicities (notably severe local reactions). It has no known marketed products and remains an experimental and discontinued antitumor agent[1][2][3][4][6][9].

Brand names

ARALDITE PT810RTEPIC G R

Other names

triglycidyl isocyanuratetris(2,3-epoxypropyl) isocyanurate1,3,5-triazine-2,4,6(1H,3H,5H)-trione, 1,3,5-tris(2,3-epoxypropyl)-alpha-triglycidyl isocyanurateteroxirone (USAN)Henkel's compound